TherapeuticsMD Inc. reported net income from continuing operations of $0.05 million, or $0.00 per basic and diluted common share, for the third quarter of 2025, compared to a net loss of $0.6 million, or $0.05 per share, in the same period of 2024. License revenue, primarily from the Mayne License Agreement, was $0.8 million, up $0.2 million from $0.5 million in the third quarter of 2024. Total operating expenses were $1.6 million, a decrease of 2.1% from the previous year. As of September 30, 2025, cash and cash equivalents totaled $7.1 million. The company continues to evaluate a range of strategic alternatives, including potential acquisitions, mergers, or other strategic transactions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112021883) on November 12, 2025, and is solely responsible for the information contained therein.